Vanguard Group Inc Evelo Biosciences, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$1.44 - $48.2 $77,824 - $2.6 Million	-54,045 Reduced 1.68%	3,168,375 $5.1 Million
Q3 2022 Nov 14, 2022	BUY	$1.86 - $41.8 $3.46 Million - $77.8 Million	1,862,098 Added 136.89%	3,222,420 $6.74 Million
Q2 2022 Aug 12, 2022	SELL	$1.46 - $3.55 $268,926 - $653,895	-184,196 Reduced 11.93%	1,360,322 $2.87 Million
Q1 2022 May 13, 2022	BUY	$2.66 - $6.63 $352,987 - $879,814	132,702 Added 9.4%	1,544,518 $5.24 Million
Q4 2021 Feb 14, 2022	SELL	$6.07 - $12.0 $510,310 - $1.01 Million	-84,071 Reduced 5.62%	1,411,816 $8.57 Million
Q3 2021 Nov 12, 2021	BUY	$6.79 - $13.9 $129,709 - $265,531	19,103 Added 1.29%	1,495,887 $10.5 Million
Q2 2021 Aug 13, 2021	BUY	$9.43 - $16.6 $13.9 Million - $24.5 Million	1,476,784 New	1,476,784 $20.3 Million

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.